Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Imaging prostate cancer lymph node metastases with a multimodality contrast agent.

Hall MA, Kwon S, Robinson H, Lachance PA, Azhdarinia A, Ranganathan R, Price RE, Chan W, Sevick-Muraca EM.

Prostate. 2012 Feb 1;72(2):129-46. doi: 10.1002/pros.21413. Epub 2011 May 2.

PMID:
21538422
2.

64Cu-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated IRDye 800CW (a near-infrared fluorescence dye) coupled to mAb7, an anti-epithelial cell adhesion molecule monoclonal antibody.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2013 Mar 5 [updated 2013 Apr 11].

3.

The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.

Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, Shariat SF, Stenzl A, Wirth M, Stief CG.

Eur Urol. 2014 Aug;66(2):191-9. doi: 10.1016/j.eururo.2013.05.033. Epub 2013 May 22. Review.

PMID:
23735200
4.

Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis.

Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F.

Eur Urol. 2013 Jun;63(6):1040-8. doi: 10.1016/j.eururo.2012.09.039. Epub 2012 Sep 25. Review.

PMID:
23036576
5.

Pelvic lymph node dissection in prostate cancer.

Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE.

Eur Urol. 2009 Jun;55(6):1251-65. doi: 10.1016/j.eururo.2009.03.012. Epub 2009 Mar 10. Review.

PMID:
19297079
6.

Molecular and functional imaging for detection of lymph node metastases in prostate cancer.

Fortuin A, Rooij Md, Zamecnik P, Haberkorn U, Barentsz J.

Int J Mol Sci. 2013 Jul 3;14(7):13842-75. doi: 10.3390/ijms140713842. Review.

7.

Imaging on nodal staging of prostate cancer.

Kilcoyne A, Price MC, McDermott S, Harisinghani MG.

Future Oncol. 2017 Mar;13(6):551-565. doi: 10.2217/fon-2016-0216. Epub 2016 Oct 27. Review.

PMID:
27785926
8.

Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges.

Thoeny HC, Barbieri S, Froehlich JM, Turkbey B, Choyke PL.

Radiology. 2017 Dec;285(3):728-743. doi: 10.1148/radiol.2017161517. Review.

PMID:
29155624
9.

Near infrared fluorescent optical imaging for nodal staging.

Sampath L, Wang W, Sevick-Muraca EM.

J Biomed Opt. 2008 Jul-Aug;13(4):041312. doi: 10.1117/1.2953498. Review.

10.

Lymphatic imaging: focus on imaging probes.

Niu G, Chen X.

Theranostics. 2015 Mar 18;5(7):686-97. doi: 10.7150/thno.11862. eCollection 2015. Review.

11.

PET imaging of recurrent and metastatic prostate cancer with novel tracers.

Mertan FV, Lindenberg L, Choyke PL, Turkbey B.

Future Oncol. 2016 Nov;12(21):2463-2477. Epub 2016 Aug 16. Review.

12.

Dual PET and Near-Infrared Fluorescence Imaging Probes as Tools for Imaging in Oncology.

An FF, Chan M, Kommidi H, Ting R.

AJR Am J Roentgenol. 2016 Aug;207(2):266-73. doi: 10.2214/AJR.16.16181. Epub 2016 May 25. Review.

Supplemental Content

Support Center